Back
Cidara Therapeutics Quote, Financials, Valuation and Earnings
The Mysterious VC Firm Behind Nvidia's Secret Weapon
Details Here!
Buy
62
CDTX
Cidara Therapeutics
Last Price:
13.12
Seasonality Move:
7.06%
7 Day Trial
ALL ACCESS PASS
$
7
Write This Down: Tuesday at 2 p.m. ET!
Don't Miss Our LIVE TradeCidara Therapeutics Price Quote
$13.12
+0.09 (+0.69%)
(Updated: November 5, 2024 at 9:40 AM ET)
Cidara Therapeutics Key Stats
Buy
62
Cidara Therapeutics (CDTX)
is a Buy
Day range:
$13.00 - $13.45
52-week range:
$10.00 - $24.40
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.51
P/B ratio:
0.7%
Volume:
20.2K
Avg. volume:
18.7K
1-year change:
-19.57%
Market cap:
$91.7M
Revenue:
$63.9M
EPS:
$-25.27
How Much Does Cidara Therapeutics Make?
-
How Much Are Cidara Therapeutics's Sales Annually?
CDTX Revenues are $63.9M -
How Much Profit Does Cidara Therapeutics's Make A Year?
CDTX net income is -$22.9M
Is Cidara Therapeutics Growing As A Company?
-
What Is Cidara Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.94% -
What Is Cidara Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Cidara Therapeutics Stock Price Performance
-
Did Cidara Therapeutics Stock Go Up Last Month?
Cidara Therapeutics share price went up by 19.54% last month -
Did CDTX's Share Price Rise Over The Last Year?
CDTX share price fell by -19.57% over the past 1 year
What Is Cidara Therapeutics 52-Week High & Low?
-
What Is Cidara Therapeutics’s 52-Week High Share Price?
Cidara Therapeutics has traded as high as $24.40 over the past 52 weeks -
What Is Cidara Therapeutics’s 52-Week Low Share Price?
Cidara Therapeutics has traded as low as $10.00 over the past 52 weeks
Cidara Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Cidara Therapeutics?
-
How Much Debt Does Cidara Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Cidara Therapeutics Have?
Cash and short term investments quarterly total is $164.4M -
What Is Cidara Therapeutics’s Book Value Per Share?
Book value per share is 28.66
Is Cidara Therapeutics Cash Flow Positive?
-
What Is CDTX Cash Flow From Operations?
Cash flow from operations (TTM) is -$124.8M -
What Is Cidara Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $239M -
What Is Cidara Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$327K
Cidara Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
CDTX return on invested capital is -449.07% -
What Is Cidara Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -135.81% -
What Is CDTX Return On Equity?
ROE is a measure of profitability and is -449.07%
Cidara Therapeutics Earnings Date & Stock Price
-
What Is Cidara Therapeutics's Stock Price Today?
A single share of CDTX can be purchased today for 13.03 -
What Is Cidara Therapeutics’s Stock Symbol?
Cidara Therapeutics trades on the nasdaq under the ticker symbol: CDTX -
When Is Cidara Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Cidara Therapeutics is scheduled on April 22, 2025 -
When Is CDTX's next ex-dividend date?
Cidara Therapeutics's next ex-dividend date is May 1, 2020 -
How To Buy Cidara Therapeutics Stock?
You can buy Cidara Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Cidara Therapeutics Competitors
-
Who Are Cidara Therapeutics's Competitors?
Below is a list of companies who compete with Cidara Therapeutics or are related in some way:
Cidara Therapeutics Dividend Yield
-
What Is CDTX Dividend Yield?
Cidara Therapeutics’s dividend yield currently is 0% -
What Is Cidara Therapeutics’s Payout Ratio?
Cidara Therapeutics’s payout ratio is 0% -
When Did Cidara Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 5, 2024 -
What Is Cidara Therapeutics’s Dividend Per Share?
Cidara Therapeutics pays a dividend of $0.00 per share
Cidara Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -556.6% |
| Revenue: | -94.07% | -76.77% |
Analyst Recommendations
| Buy Recommendations: | 1 |
|---|---|
| Hold Recommendations: | 0 |
| Sell Recommendations: | 0 |
| Price Target: | 24.50 |
| Upside from Last Price: | 88.03% |